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Abstract
Background: This is the first report of the incidence and causes of end-stage renal disease (ESRD) of the Turkish-Cypriot
population in Northern Cyprus.
Methods: Data were collected over eight consecutive years (2004–2011) from all those starting renal replacement therapy
(RRT) in this population. Crude and age-standardised incidence at 90 days was calculated and comparisons made with other
national registries. We collected DNA from the entire prevalent population. As an initial experiment we looked for two
genetic causes of ESRD that have been reported in Greek Cypriots.
Results: Crude and age-standardised incidence at 90 days was 234 and 327 per million population (pmp) per year,
respectively. The mean age was 63, and 62% were male. The age-adjusted prevalence of RRT in Turkish-Cypriots was 1543
pmp on 01/01/2011. The incidence of RRT is higher than other countries reporting to the European Renal Association –
European Dialysis and Transplant Association, with the exception of Turkey. Diabetes is a major cause of ESRD in those
under 65, accounting for 36% of incident cases followed by 30% with uncertain aetiology. 18% of the incident population
had a family history of ESRD. We identified two families with thin basement membrane nephropathy caused by a mutation
in COL4A3, but no new cases of CFHR5 nephropathy.
Conclusions: This study provides the first estimate of RRT incidence in the Turkish-Cypriot population, describes the
contribution of different underlying diagnoses to ESRD, and provides a basis for healthcare policy planning.
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Introduction
In recent years end-stage renal disease (ESRD) has become an
increasing public health challenge for high and middle income
countries, with an associated escalation of the cost of providing
renal replacement therapy (RRT) [1–4]. The collection of
accurate epidemiological data is of great importance for healthcare
policy planning [1–3]. This is especially true for places where the
infrastructure delivering RRT is improving, such as the island of
Cyprus.
There are considerable differences in the incidence and
prevalence of RRT within Europe. Registry data demonstrate a
North-South gradient, with higher incidence of RRT and lower
mortality around the Mediterranean [2,5]. Several factors have
been suggested to contribute to this variation [6,7]. In order to
understand the aetiology of ESRD and chronic kidney disease,
which affects many more people, it is important to determine the
primary renal diagnosis [8]. ESRD attributed to type 2 diabetes
and hypertension continues to rise throughout the world, and this
is increasingly true for countries such as Cyprus [2,9–11].
Cyprus is an island in the eastern Mediterranean that has been
occupied by a series of historical powers, in particular the Greeks
and Ottoman Turks. The Cypriot population is genetically distinct
from mainland populations of either Greece or Turkey, although
environmental factors, such as diet and lifestyle are broadly similar
[12,13].
Turkish-Cypriots form a distinct ethno-linguistic community
centered on Turkish administered Northern Cyprus (TRNC). The
aim of this study was to describe the incidence and prevalence of
RRT in this ethnically-defined Mediterranean population by type
of primary renal disease. To put these data into context we
compared these data with reported RRT incidence from Greece,
Turkey, and the white population of England. An important, and
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probably unique, aspect of our registry is that every RRT patient
has provided a DNA sample for research. Because the Greek and
Turkish communities share many genetic characteristics [14,15],
we initially undertook genetic testing for two conditions that have
been identified in Greek Cypriots, CFHR5 nephropathy and thin
basement membrane nephropathy [16,17].
Materials and Methods
Ethics Statement
This study was approved by the ethics committee of Lefkosa
Burhan Nalbantog˘lu State Hospital. All participants provided
informed consent in writing, in accordance with the Declaration of
Helsinki.
Study Population
The study was conducted at Nicosia State Hospital in Northern
Cyprus. Nicosia State Hospital is a multi-specialty tertiary care
hospital, and provides renal services to the whole of Turkish
administered Northern Cyprus (TRNC). All citizens of TRNC are
entitled to free RRT, regardless of ethnicity. All patients with
symptomatic chronic kidney disease (CKD) from within this
population present either through the village practitioners, private
hospitals or directly to Nicosia State Hospital. Details of every
individual admitted with acute or chronic renal failure in the last
decade were collected with a unique identifier number, thus
preventing any duplication of records or redundancy of referrals.
ESRD was defined as chronic renal disease with an eGFR of
,10 ml/min/1.73 m2; but patients with diabetic nephropathy
often started RRT with eGFR,15 ml/min/1.73 m2.
The most recent census of the TRNC population in 2006
showed that of 178,031 de jure citizens, 120,007 were born to
parents who were both themselves born in Cyprus, providing an
effective measure of the size of the ethnic Turkish-Cypriot
population that has been applied throughout this paper [18].
Variables
Basic demographic data (age at ESRD, sex, ethnic group, and
probable diagnosis) were recorded for all patients receiving RRT
at day 1, and again after 90 days on the renal replacement
programme. Diabetic nephropathy was defined as ESRD in the
presence of diabetes without evidence of an alternative diagnosis.
Family history of ESRD was defined as a first or second degree
relative with ESRD.
Data Sources for International Comparisons
European data was taken from the European Renal Association
– European Dialysis and Transplant Association (ERA-EDTA)
Registry report for 2008 [2]. Additional data for Greece, Turkey,
and England were taken from the Hellenic Renal Registry (Dr GA
Ioannidis personal communication), the National Haemodialysis,
Transplantation and Nephrology Registry report of Turkey 2008
[19], and the 2008 Renal Registry Report [1]. The denominator
population for international comparisons was calculated from the
relevant national statistics [20,21].
Statistical Analysis
The incidence of RRT in this population was averaged over
eight consecutive calendar years (2004–2011). Age-standardised
incidence rates were calculated using the Eurostat EU27
population figures [22]. All comparisons with other populations
were made using data for chronic RRT; that is those still on RRT
at 90 days. The emphasis of this report will be on age-specific
comparisons as these are not affected by age-referral biases. We
calculated 95% confidence intervals assuming a Poisson distribu-
tion for incidence rates. Statistical analysis was carried out using
Stata version 11.
Genetic Testing of All Adult Patients on RRT in North
Cyprus
After informed consent for this study, blood was taken from all
patients on renal replacement therapy on 01/01/2011. Genetic
analysis was performed at University College London, UK. DNA
was extracted from peripheral blood using the QIAamp DNA
Blood Mini Kit (Qiagen, Stanford, CA, USA). We designed
primers to screen for the G1334E and 3854delG mutation in
COL4A4 and the G871C mutation in COL4A3 [23]. Screening
PCR was also performed to amplify both wild-type and mutant
CFHR5 alleles in a single reaction as described previously [16].
Results
A total of 225 Turkish-Cypriot patients were maintained on
renal replacement therapy beyond 90 days during the study period
(01/01/04–31/12/11). More males than females started RRT
(139 vs 86), but the age distribution was similar between the sexes
(Table 1). 18.2% of the incident population had a first or second
degree relative with ESRD, and this rose to 27% in those with
ESRD due to uncertain aetiology. The average crude and age-
standardised incidence rates at day 1 for this period were 311.4
and 456.9 per million population, respectively. The Turkish-
Cypriot case mix at 90 days included 36.0% with ESRD due to
diabetic nephropathy, 29.8% with unknown diagnosis, and 3.6%
with polycystic kidney disease (Table 2). Tetra primer PCR
identified two individuals on RRT with the G871C mutation in
COL4A3 previously reported in Greek-Cypriot pedigrees [17].
We did not detect the other previously cited mutations in COL4A3
and COL4A4 or the CFHR5 duplication in the RRT population
[16,17].
The majority (91.1%) of Turkish-Cypriot patients started RRT
on haemodialysis; only a few started peritoneal dialysis (4.4%) or
had pre-emptive renal transplantation (3.5%) (Table 1). The crude
and age-standardised prevalence of RRT in Turkish-Cypriots was
1216 and 1543 pmp, respectively. The median age of the Turkish-
Cypriot prevalent population was 60 for both men and women,
and the mean duration on RRT was 5.0 years. The majority of
patients on RRT in Northern Cyprus are treated with hemodi-
alysis, which is carried out in two centers, Nicosia and Famagusta.
The proportion of prevalent patients on peritoneal dialysis (14%) is
similar to other countries [24]. Renal transplantation is performed
in either Turkey or the Republic of Cyprus (Greek Cypriot), and
benefits a high proportion of patients (prevalence 376 pmp).
We carried out international comparisons. Turkey, Greece, and
Tunisia have an age-adjusted incidence rate at day 90 of 349.1,
159.5, and 238.7 pmp respectively [2]. In comparison the crude
and age-adjusted incidence rates of chronic RRT for Turkish-
Cypriots were 234.4 and 327.2 per million population, respec-
tively. Figure 1 shows that the incidence of RRT in each age group
in Turkish-Cypriots is comparable to that seen in Turkey. Despite
the small number of cases, the incidence of RRT in the 45–64 age
group in Turkish-Cypriots (412.0 pmp) is significantly higher than
that seen in the white population of England (123.2 pmp).
There is a high rate of RRT for ESRD attributed to diabetic
nephropathy in all eastern Mediterranean countries (84.4 pmp in
Turkish-Cypriots, 53.5 pmp in Greece, and 61.6 pmp in Turkey)
(Table 2). Table 2 also shows that the code ‘uncertain aetiology’ is
more common in the Turkish-Cypriot registry (69.8 pmp) than in
other populations. However there were lower levels of hyperten-
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sive nephropathy in Turkish-Cypriots than in Greece or Turkey
(1.0 pmp vs 19.1 pmp and 53.4 pmp respectively). The incidence
of polycystic kidney disease was broadly similar across all registries
(range 6.7–10.1 pmp).
The incidence of RRT in the minority Turkish population of
Northern Cyprus is broadly in line with the rate seen in Turkish-
Cypriots. An additional 76 Turkish patients were maintained on
renal replacement therapy beyond 90 days during the study
period, giving an overall incidence of 211.3 pmp in the de jure
population of Northern Cyprus. However data on this population
is less accurate due to significant migration to and from the
mainland of Turkey [18].
Discussion
High Incidence of RRT
This study presents the first population-based RRT incidence
figure from Cyprus, and reveals a high incidence of RRT that is
RRT is higher than other countries reporting to the ERA-EDTA,
with the exception of Turkey [2]. Diabetes is a major cause of
ESRD overall and specifically in those under 65, with rates
comparable to those seen in the USA [3]. We found that the high
incidence of RRT in Turkish-Cypriots is not due to the specific
mutations in COL4A3, COL4A4, and CFHR5 assessed in this study
[16,17]. Finally, a third of Turkish-Cypriot patients start RRT
with unknown primary diagnosis. This highlights both the need for
earlier detection of these cases and the possibility that there may
be other uncharacterised conditions causing ESRD in this
population.
Table 1. Baseline characteristics of the incident Turkish-Cypriot renal replacement therapy (RRT) population at 90 days.
Characteristic Category Number Percentage
Gender Male 139 61.7%
Female 86 38.3%
Median age of adult population at ESRF in years
(lower and upper quartile)
Male 63 (54,69)
Female 64 (52,74)
Modality of RRT at presentation Haemodialysis 205 91.1%
Peritoneal dialysis 10 4.4%
Renal transplant 8 3.5%
Co-morbidities Diabetes 93 41.3%
Hypertension 145 64.4%
Family History 41 18.2%
Mutation Analysis COL4A3 (G871C) 2 0.9%
COL4A3 (G1334E) 0 0%
COL4A4 (3856delC) 0 0%
CFHR5 duplication 0 0%
doi:10.1371/journal.pone.0054394.t001
Table 2. Provisional renal diagnosis in the Turkish-Cypriot renal replacement therapy (RRT) population at 90 days, by incidence
per million population and percentage, in comparison with 2008 registry data for Greece, Turkey, and the UK.
Turkish-Cypriots Greece Turkey England whites
Diagnosis pmp % pmp % pmp % pmp %
Diabetes 84.4 36.0% 53.5 30.3% 61.6 29.9% 24.5 19.5%
Glomerulonephritis 29.2* 12.4%* 14.8 8.4% 16.4 7.9% 13.5 10.7%
Hypertension 1.0 0.4% 19.1 10.8% 53.4 25.9% 6.8 5.4%
Renal Vascular Disease 12.5 5.3% 3.0 1.7% 2.8 1.3% 7.8 6.2%
Data not available 0.0 0.0% 0.0 0.0% 3.1 1.5% 9.8 7.8%
Other identified Category 12.5 5.3% 15.7 8.9% 21.0 10.2% 18.2 14.5%
Pyelonephritis 16.7 7.1% 9.9 5.6% 7.6 3.7% 9.7 7.7%
Polycystic Kidney 8.3 3.6% 6.7 3.8% 7.8 3.8% 10.1 8.0%
Uncertain aetiology 69.8 29.8% 53.9 30.5% 32.5 15.7% 25.5 20.3%
Total incidence at day 91 234.4 100.0% 176.7 100.0% 206.2 100.0% 125.9 100.0%
*Includes presumed glomerulonephritis not biopsy proven.
doi:10.1371/journal.pone.0054394.t002
End-Stage Renal Disease in Cyprus
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Diabetic Nephropathy
The Turkish-Cypriot case-mix, with a high incidence of RRT
for ESRD due to diabetic nephropathy, is similar to that seen in
Turkey and Greece (Table 2). Diabetes is also a common cause of
ESRD in developing countries around the Eastern Mediterranean,
such as Egypt, Kuwait, Lebanon and Saudi Arabia [11]. The
incidence of RRT for ESRD attributed to diabetic nephropathy
seen in Turkish-Cypriot less than 65 years old is striking (Figure 2).
Currently data concerning the incidence of diabetes in Turkish-
Cypriots is lacking. Diabetes is common in Greek-Cypriots and
mainland Turkish patients [25–27], but not to the extent seen in
some other populations with high levels of diabetic nephropathy,
such as the Pima Indians of Arizona [28,29]. Moreover, childhood
levels of obesity in Cyprus are much closer to those seen in other
European countries than in the US [30,31]. It is therefore possible
that, in common with other registries, some of these cases reflect a
co-occurrence of Type 2 diabetes with ESRD due to an alternative
aetiology [32].
Genetic Renal Disease in the Turkish-Cypriot Population
Congenital factors may also be important in the aetiology of
ESRD in this population [33]. Previous estimates of the prevalence
of family history of ESRD amongst incident dialysis patients,
suggest that 7–15% Caucasians have a first or second-degree
relative with ESRD [34,35]. This proportion is highest in young
adults, non-Caucasians, and for those where ESRD is caused by
diabetes or hypertension [34]. We observed a similar rate of
familial ESRD in Turkish-Cypriot patients on RRT, which was
even higher (27%) in the group with unknown diagnosis,
suggesting the existence of conditions that are not yet char-
acterised in this population. For comparison, the rate of RRT for
ESRD due to polycystic kidney disease was similar across all
registries.
In order to assess the contribution of inherited renal disease we
collected DNA from the entire Turkish-Cypriot population on
RRT. Previous work has demonstrated a number of important
founder mutations and significant geographic clustering for several
monogenetic diseases affecting the Greek-Cypriot population of
Cyprus, including mutations of COL4A3, COL4A4, PKD2, and
MEFV [17,36,37]. Although the CFHR5 duplication is common in
Figure 1. Incidence of renal replacement therapy (RRT) at 90 days by age and gender. Incidence of RRT at 90 days in Turkish Cypriots
compared with 2008 registry data for Greece, Turkey, and English whites in males (A), and females (B). Error bars indicate 95% confidence intervals.
doi:10.1371/journal.pone.0054394.g001
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Figure 2. Incidence of renal replacement therapy (RRT) for end stage renal disease (ESRD) due to diabetic nephropathy. Incidence of
RRT for ESRD due to diabetic nephropathy (DN) and all other causes (Non-DN) at 90 days in Turkish Cypriots compared with 2008 registry data for
Greece, Turkey, and English whites in 20–44 year olds (A), 45–64 year-olds (B), and those over 65 years (C). Error bars indicate 95% confidence
intervals.
doi:10.1371/journal.pone.0054394.g002
End-Stage Renal Disease in Cyprus
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Greek-Cypriots originating from the southern half of the island
[38], we did not detect it in our sample of prevalent patients.
However, due to the small size of our sample the allelic frequency
may still lie within that observed for Greek Cypriots [39]. The
familial clustering and high incidence of RRT in Turkish-Cypriots
is therefore due to other monogenetic or polygenic diseases in this
population.
Coding ‘Uncertain Aetiology’
There is a significant group in the Turkish-Cypriot RRT
population with unknown diagnosis (69.8 pmp). This group partly
reflects late presentation and limited diagnostic investigations.
Comparative data from the Eastern Mediterranean is difficult to
obtain, and information on primary renal disease is less robust
[8,32] but there is evidence for a reciprocal relationship with
coding for hypertension in many registries [8,32,40]. The
incidence of hypertensive nephropathy is conspicuously lower in
Turkish-Cypriots than in neighbouring countries. In the absence
of clear diagnostic criteria for hypertensive nephropathy, it may be
appropriate to combine ‘hypertension’ with ‘uncertain aetiology’
in Table 2, which would imply that there is no established primary
renal diagnosis in 40% of patients on RRT in the Greek, Turkish,
and Turkish-Cypriot registries.
The majority of patients with an unknown diagnosis present
clinically with minimal proteinuria (,1 g protein/day) and
asymptomatic disease, consistent with a pathological process
primarily affecting the renal tubules [8] and similar to the features
of medullary cystic kidney disease type 1. A number of families
presenting this way in the Greek Cypriot population have shown
linkage to the region 1q21, but the gene responsible has not yet
been identified [41]. It is possible that the medullary cystic
phenotype reflects the final common pathway of a number of
genetic and environmental factors that are common in this
population.
Alternative Explanations for the Incidence of RRT in
Turkish-Cypriots
Regional variations in RRT incidence may reflect both genetic
and environmental factors [7,28,42]. Macroeconomic factors that
influence regional variations in RRT incidence include per capita
GDP and health-care expenditure [7]. Northern Cyprus has a
developing economy, with per-capita GDP that is 76% of that in
the Republic of Cyprus, and it is dependent on aid from the
Turkish government [43]. RRT has only recently become widely
available in TRNC and there is no long-term provision of private
dialysis. Economic factors also influence the management of CKD
and co-morbidities, as well as the competing risk of mortality, in
the general population [7]. The high incidence of RRT in the
Turkish-Cypriot population may therefore reflect suboptimal
management of diabetes, hypertension, and associated complica-
tions. This has significance for healthcare planning on the island,
and underlines the importance of prospective assessment of kidney
function in this population.
Wider Relevance of these Findings
Our findings have several implications. First, these data
highlight the need to examine the care of diabetics who are at
risk of renal disease in the Turkish-Cypriot population, particu-
larly in young people, to prevent rising rates of RRT. To this end,
we are examining case records of patients who were diagnosed
with diabetic nephropathy and reached ESRD at a young age.
Second, there is a large diaspora of Turkish-Cypriots who may
carry with them an increased risk of ESRD. Third, this study
provides a template for other adult registries across the Middle-
East, and highlights the proportion of patients with unknown
diagnosis [8]. It is hoped that with greater access to diagnostic
investigations this number will be reduced further.
The strength of this study is that we have a complete dataset
from the study period, including DNA samples from the entire
prevalent RRT population. Many countries with new RRT
programs, such as Bangladesh or Malaysia, show increasing take-
up of services with time [24]. However the incidence rate, mean
age, and sex-ratio of patients on RRT at 90 days shown in Table 1
are broadly in line with other European populations [2].
Moreover, by examining incidence at 90-days in those aged
,65 years we have sought to avoid misclassification and bias due
to referral patterns, availability of RRT, and prevalence of co-
morbidities.
The main limitations of this study are factors affecting the
calculation of incidence rates. This study used the same definition
of ethnicity as the 2006 census, and the size of the population
remained stable over the study period. Referral bias is unlikely as
RRT is freely available to all citizens, and because all ERSD is
managed through one centre we were able to achieve a
remarkably complete dataset.
In conclusion, this study provides a complete dataset of RRT in
the Turkish-Cypriot population and shows that incidence and
prevalence of RRT are high. Diabetes is a major cause of ESRD
overall and specifically in those under 65. With the prevalence of
diabetes and hypertension projected to rise further, facilities to
target the earlier stages of diabetes and CKD need to be developed
further in this population. Earlier identification of CKD together
with long-term follow-up will enable more accurate determination
of renal diagnosis before the onset of ESRD. Familial renal disease
is common in this population, and this study represents the first
complete collection of DNA from an ethnically-defined population
on RRT. This population therefore provides an opportunity to
look for genetic factors associated with an increased risk of ESRD
in Cyprus. The high prevalence of RRT in Turkish-Cypriots has
implications for healthcare policy planning.
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